Gilead Sciences

At the Wells Fargo Healthcare Conference, Gilead presented an expanded growth plan with three strategic pillars: virology, oncology and inflammatory medicine, with HIV remaining the core business. The company reported a full pipeline and several upcoming launches in late 2026/2027, highlighted Anito‑cel (CAR‑T) with a differentiated safety profile and strong growth signals in PrEP and TRODELVY revenues. Gilead emphasized the need for selective prioritization within its broad pipeline and plans further data readouts as well as potential partnerships and external transactions. » Mere på de.investing.com

Assembly Biosciences has exercised its option and will assume 40% of U.S. development costs and profits for the helicase–primase inhibitor program against herpes, while Gilead will handle clinical development and commercialization. Assembly secures rights to up to $280 million in milestone payments and tiered royalties outside the U.S.; additionally, a $75 million payment from Gilead in Q4 2026 extends the company’s cash runway to 2029. Lead candidate GS-1179 was selected for further development and provides a phase‑2 catalyst; the shares rose 4.9% in after-hours trading to $37. » Mere på de.investing.com

Gilead secured three FDA approvals in the past four months, most recently for Bixlenvo for virologically suppressed adults with HIV, adding to approvals for Trodelvy and Hepcludex. Near-term catalysts include PDUFA target dates for anito-cel (Dec. 23) and once-weekly oral Yeztugo for PrEP (Feb. 2), plus a planned 2027 launch of a weekly lenacapavir-islatravir combo. The company reported Q2 revenue of $7.6 billion (up 8% y/y), raised its quarterly dividend to $0.82, executed buybacks, and posted gross margins near 87%, supporting management’s case for durable cash generation despite HIV-related concentration risks. » Mere på finance.yahoo.com